Adi Mor
Chief Executive Officer at CHEMOMAB THERAPEUTICS LTD.
Net worth: 18 723 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stephen P. Squinto | M | 67 |
Chemomab Ltd.
 Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | 1 years |
| Nissim Darvish | M | 59 |
Chemomab Ltd.
Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | 3 years |
| Neil Cohen | M | 60 | 4 years | |
| Sigal Fattal | F | 53 | 4 years | |
| Claude Nicaise | M | 71 | 3 years | |
| Alan Moses | M | 76 | 3 years | |
| Barbara Lindheim | F | - | - | |
| Nissim Mashiach | M | 63 |
Chemomab Ltd.
Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | - |
| Sharon Hashmueli | M | - | 8 years | |
| Jill Quigley | F | 49 | 2 years | |
| Jason Camm | M | 35 |
Chemomab Ltd.
Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | - |
| Jack Lawler | M | - | 2 years | |
| Ilan Vaknin | M | - | 2 years | |
| Matthew B. Frankel | M | 56 | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Dale Pfost | M | - | 2 years | |
| Donald Marvin | M | - | 2 years | |
| Jacob George | M | 59 |
Chemomab Ltd.
Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | - |
| Joel Maryles | M | 64 | 1 years | |
| Sharon Elkobi | F | - | 3 years | |
| Bryan Jennings | M | - |
Chemomab Ltd.
Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | 1 years |
| Efrat Makov | F | 56 | 2 years | |
| David Ben-Ami | M | 63 |
Chemomab Ltd.
Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | 4 years |
| Mitchell Jones | M | 46 | - | |
| Arnon Aharon | M | 55 | 5 years | |
| David Weiner | M | 59 | 1 years | |
| Michal Segal-Salto | M | 51 | 7 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Israel | 7 | 26.92% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Adi Mor
- Personal Network
